Raymond James, Third Harmonic

Raymond James Downgrades Third Harmonic Bio (THRD)
Fintel reports that on February 11, 2025, Raymond James downgraded their outlook for Third Harmonic Bio (NasdaqGM:THRD) from Outperform to Market Perform. Analyst Price Forecast Suggests 433.54% Upside As of January 29,
Morgan Stanley, Raymond James target new assets in 2025
The next CEO of Raymond James talks about how private equity ownership has made for some difficult marriages in wealth management, while a Morgan Stanley exec says asset outflows were unusually high last year.
Raymond James downgrades Third Harmonic Bio on uncertainty for only asset
As previously reported, Raymond James downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform and removed the firm’s prior $18
Haemonetics price target lowered to $115 from $120 at Raymond James
Raymond James lowered the firm’s price target on Haemonetics (HAE) to $115 from $120 and keeps a Strong Buy rating on the shares. Shares sold
Boston Scientific price target raised to $119 from $101 at Raymond James
Raymond James raised the firm’s price target on Boston Scientific (BSX) to $119 from $101 and keeps a Strong Buy rating on the shares. Boston Scientific is still one of the most dynamic companies in MedTech,
Third Harmonic stock rating cut by Raymond James
James made a notable change in their assessment of Third Harmonic (NASDAQ:HLIT) Bio (NASDAQ:THRD), downgrading the biotechnology company's stock rating from Outperform to Market Perform. According to InvestingPro data,
Third Harmonic Bio downgraded to Market Perform from Outperform at Raymond James
Raymond James downgraded Third Harmonic Bio (THRD) to Market Perform from Outperform. Published first on TheFly – the ultimate source for
Raymond James Downgrades ConocoPhillips (COP)
Fintel reports that on February 10, 2025, Raymond James downgraded their outlook for ConocoPhillips (NYSE:COP) from Strong Buy to Outperform. Analyst Price Forecast Suggests 37.63% Upside As of January 28,
Raymond James Forecasts Strong Price Appreciation for Amazon.com (NASDAQ:AMZN) Stock
Amazon.com (NASDAQ:AMZN) had its price objective boosted by equities researchers at Raymond James from $260.00 to $275.00 in ...
GovCon Wire22h
Raymond James’ Andy McEnroe on Post-Election GovTech Market
Uncover why the promises of the second Trump administration have contractors concerned about spending and acquisition funding ...
Palantir or AMD: Raymond James Chooses the Better AI Stock to Buy After Earnings
January finished with an earthquake in the tech world, when the Chinese startup DeepSeek released its new AI assistant – and ...
Raymond James Has Negative Outlook of TSE:CF FY2025 Earnings
Stock analysts at Raymond James lowered their FY2025 EPS estimates for shares of Canaccord Genuity Group in a report issued ...
Raymond James: Strong Balance Sheet And Cash Economics Are In The Price
Raymond James is seeing a beneficial shift to advisory as well as recovering M&A activity, which may continue. Read why I ...
InvestmentNews5d
LPL, Raymond James boost advisor ranks anew
LPL Financial welcomes a $345 million investment and planning team from Ameriprise as RayJay's employee advisor arm adds a ...
Raymond James lifts USAC stock target to $30; maintains outperform
James analyst James Rollyson updated his outlook on USA Compression Partners LP (NYSE:USAC), raising the firm's price target on the stock to $30.00, up from the previous $27.00, while reiterating an ...
Q1 EPS Estimates for FirstService Reduced by Raymond James
Analysts at Raymond James lowered their Q1 2025 earnings estimates for shares of FirstService in a note issued to investors on Thursday, February 6th. Raymond James analyst F. Bastien now anticipates ...